Data Items Collected The following variables were charted for each included source of evidence: Bibliographic information: author, year, country, funding Study characteristics: design, phase, sample size, duration, setting Population: diabetes type, overweight/obesity definitions, CKD stage, albuminuria status, baseline eGFR, concomitant therapies Intervention(s) or exposure: GLP-1 receptor agonist or tirzepatide (dose, route, duration) Comparator(s): placebo or active comparator Outcomes: kidney and cardiorenal measures (eGFR slope, composite renal endpoints, albuminuria, safety) Main findings: direction and magnitude of renal effect Appraisal and evidence rating: methodological quality, certainty, and relevance Notes: contextual remarks, analytic subgroups, and comments on applicability Appraisal and Evidence Rating Because this review was conducted to inform the RAND/UCLA Appropriateness Method for SLANH, each included study underwent a structured critical appraisal using the appropriate validated tool for its design: Randomized controlled trials: Cochrane Risk of Bias 2 (RoB 2) [10] Post hoc or secondary RCT analyses: adapted Cochrane or NIH tool Observational comparative studies: ROBINS-I [11] The AI tool was programmed to assist in pre-classifying bias domains (e.g., randomization, blinding, confounding) and to highlight textual evidence for reviewer judgment

Each step up delivers roughly three additional percentage points
We should talk about ways to modify this if it's something you care about, and maybe you should care about it if it's going to shorten your lifespan. That discussion needs to occur early on, not when you finally notice when the patient can't get through your office door
In addition, the second cycle of IRA drug-pricing negotiations resulted in agreements for a 71% discount for three well-known GPI-1s, Wegovy, Ozempic and Rybelsus that will take effect on January 1, 2027
Vitamin E: Emerging aspects and new directions
While marketed as an anti-aging therapy, more robust studies are needed to validate these claims